“PRECISION aims to enable patients and clinicians to make informed, biology-based decisions to avoid unnecessary and burdensome treatment of indolent DCIS. The answer can only be found by synergistic collaboration between leading scientists, clinicians and patient advocates.
– Prof. Dr. Jelle Wesseling, Senior Group Leader, The Netherlands Cancer Institute, Amsterdam; Professor of Breast Pathology, Leiden University Medical Center, Leiden, The Netherlands
There is a wide spectrum of DCIS ranging from low to high risk. “Low-risk” means it is more likely to be harmless and not progress to invasive breast cancer. “Low-risk” includes low and intermediate grades (1 and 2), as well as other physical and biological features which have a low potential for progression to a future invasive cancer. “Low-risk” DCIS differs greatly from “high-risk” DCIS which some research has shown to be faster growing and more closely associated with a future invasive breast cancer.”
PRECISION Patient Advocates
Click the link below to read about this “Grand Challenge” project as well as the important role of Patient Advocates:
I am originally from New Jersey and moved to Los Angeles with my family at age 12. After graduating from San Diego State University with a BA in Journalism, I had a short-stint in magazine advertising sales before landing my "dream job" with Club Med. For two years I worked at resorts in Mexico, The Bahamas, The Dominican Republic and Colorado. My husband Glenn & I met in Ixtapa, Mexico and we embarked on a two year honeymoon around the world. This was also a research project for a book we wrote called "When The Travel Bug Bites: Creative Ways to Earn, Save and Stay Abroad." I am also the author of a quote book for new graduates -- "Cheatnotes on Life: Lessons From The Classroom of Life." In 1997, we settled in San Diego and I was blessed to work part-time from home for non-profit organizations while raising our two boys. In 2010, a DCIS diagnosis changed my life. DCIS 411 is the culmination of my on-going journey and discoveries.